Nitric oxide (NO) donors are pharmacologically active substances that release NO in vivo or in vitro. NO has a variety of functions such as the release of prostanoids, inhibition of platelet aggregation, effect on angiogenesis, and production of oxygen free radicals. This report discusses the chemical and pharmacological characteristics of NO donors, their effect on platelet function and cyclooxygenase, their cardiac action including myocardial infarction, and release of superoxide anions. This review stresses NO tolerance and the effect of NO donors on angiogenesis in myocardial infarction and in solid tumors.
Get full access to this article
View all access options for this article.
References
1.
FurchgottRF, ZawadzkiJV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature288: 373–376, 1980.
2.
IgnarroLJ, LipptonH, EdwardsJC, BaricosWH, HymanAL, KadowitzPJ, GruetterCA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther218: 739–749, 1981.
3.
YamamotoT, KakarNR, VinaER, JohnsonPE, BingRJ. The effect of aspirin and two NO donors on the infarcted heart in situ.Life Sci67: 839–846, 2000.
4.
SalveminiD, CurrieMG, MollaceV.Nitric oxide-mediated cyclooxygenase activation: A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest97: 2562–2568, 1996.
5.
MoncadaS.Nitric oxide in the vasculature: Physiology and pathophysiology. Ann N Y Acad Sci811: 60–67, 1997.
6.
HariawalaMD, SellkeFW. Angiogenesis and the heart: Therapeutic implications. J R Soc Med90: 1022–1028, 1997.
7.
FreemanB.Free radical chemistry of nitric oxide: Looking at the dark side. Chest105: 79S–83S, 1994.
8.
CuzzolinL, AdamiA, DeganM, CrivellenteF, BonapaceS, MinuzP, BenoniG.Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats. Life Sci38: 207–210, 1996.
9.
RapoportRM, MuradF.Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res52: 352–357, 1983.
10.
ChungS-J, FungH-L.Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther253: 614–619, 1990.
11.
TorfgardKE, AhlnerJ.Mechanisms of action of nitrates. Cardiovasc Drugs Ther8: 701–717, 1994.
12.
HillJA, HuntRWJr.. JonesR, HooverRL, BurkRE. Metabolism of nitroglycerin by smooth muscle cells: Involvement of glutathione and glutathione S-transferase. Biochcm Pharmacol43: 561–566, 1992.
13.
FeelischM, OstrowskiJ, NoackE.On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol14(Suppl 11): S13–S22, 1989.
14.
RosenkranzB, WinkelmannR, ParnhamMJ. Clinical pharmacokinetics of molsidomine. Drug Metab Dispos30: 372–384, 1990.
15.
BatesJN, BakerMT, GucrraRJr., HarrisonDG. Nitric oxide generation from nitroprusside by vascular tissue. Biochcm Pharmacol42(Suppl): S157–S165, 1991.
16.
MarksGS, McLaughlinBE, JimmoSL, PoklcwskaKoziellM, BrienJF, NakatsuK.Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine but not by glyceryl trinitrate. Drug Metab Dispos23: 1248–1252, 1995.
17.
HarrisonDG, BatesJN. The nitrovasodilators: New ideas about old drugs. Circulation87: 1461–1467, 1993.
18.
JansenA, DrazenJ, OsbornJA, BrownR, LoscalzoJ, StamlerJS. The relaxant properties in guinea pig airways of S-nitrosothiols. J Pharmacol Exp Ther261: 154–160, 1992.
19.
ScorzaG, PietraforteD, MinettiM.Role of ascorbate and protein thiols in the release of nitric oxide from S-nitroso-alubumin and S-nitroso-glutalhione in human plasma. Free Radic Biol Med22: 633–642, 1997.
20.
JiaL, BlantzRC. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats. Eur J Pharmacol354: 33–41, 1998.
21.
FeelischM.The biochemical pathways of nitric oxide formation from nitrovasodilators: Appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol17: S25–S33, 1991.
HansonSR, HutseilTC, KeeferLK, MooradianDL, SmithDJ. Nitric oxide donors: A continuing opportunity in drug design. Adv Pharmacol34: 383–398, 1995.
24.
WallaceJL, McKnightW, CirinoG, Del SoldatoP, DaviesNM. Nitric oxide-releasing aspirin derivative (NCX 4016): A gastric-sparing antithrombotic drug, (abstract)Gastroenterology112: A325, 1997.
25.
WhittleBRJ. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis and gastrointestinal damage induced by indomethacin in the rat. Gastroenterology80: 94–98, 1981.
26.
WallaceJL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology112: 1000–1016, 1997.
27.
LechiC, AndrioliG, GainoS, TommasoliR, ZulianiV, OrtolaniR, DeganM, BenoniG, BellaviteP, LechiA, MinuzP.The antiplatelet effect of a new nitroderivative of acetylsalicylic acid: An in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thromb Haemost76: 791–798, 1996.
28.
DiodatiJ, ThérouxP, LatourJ, LacosteL, LamJYT, WatersD.Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol66: 683–688, 1990.
29.
FranchiAM, ChaudM, RettoriV, SuburoA, McCannSM, GimenoM.Role of nitric oxide in eicosanoidc synthesis and uterine motility in estrogen-treated rat uteri. Proc Natl Acad Sci U S A91: 539-–543, 1994.
30.
DavidgeST, BakerPN, McLaughlinMK, RobertsJM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res77: 274–283, 1995.
31.
DariusH, AhlandB, RuckcrW, KlausW, PeskarBA, SchrorK.The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro: Inhibition of 12-HPETE biosynthesis. J Cardiovasc Pharmacol6: 115–1211984.
32.
OvizeM, LorgerilM, CathignolD, DclaycJ, RenaudS.Inhibition of coronary artery thrombosis by SIN-1, a donor of nitric oxide. J Cardiovasc Pharmacol16: 641–645, 1990.
33.
SchrörK, GrodzinskaL, DariusH.Stimulation of coronary vascular prostacyclin and inhibition of human platelet thromboxane after low-dose nitroglycerin. Thromb Res23: 59–67, 1981.
34.
SalasE, MoraMA, AskewS, HodsonHF, ButlerAR, RadomskiMW, MoncadaS.Comparative pharmacology of analogues of S-nilroso-N-acctyl-DL-pcnicillaminc on human platelets. Br J Clin Pharmacol112: 1071–1076, 1994.
35.
WallaceJL, McKnightW, SoldatcPD, BaydounAR, CirinoG.Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest96: 2711–2718, 1995.
36.
LechiC, GainoS, TomasoliR, ZulianiV, BonapaceS, FontanaL, DeganM, LechiA, MinuzP.In vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Blood Coagul Fibrinolysis7: 206–209, 1996.
37.
GuoY, JonesWK, XuanY, TangX, BaoW, WuW, HanH, LaubachVE, PingP, YanZ, QiuY, BolliR.The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A96: 11507–11512, 1999.
38.
NodeK, KitakazeM, KosakaH, KomamuraK, MinaminoT, InoueM, TadaM, HoriM, KamadaT.Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation93: 356–364, 1996.
39.
NakanoA, LiuGS, HeuschG, DowneyJM, CohenMV. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide if not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol32: 1159–1167, 2000.
40.
BalligandJL, UngureanuD, KellyA, KobzikL, PimentaiD, MichelT, SmithTW. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest91: 2314–2319, 1993.
41.
PablaR, CurtisMJ. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res77: 984–992, 1995.
42.
LjusegrenME, AxelssonKL. Lactate accumulation in isolated hypoxic rat ventricular myocardium: Effect of different modulators of the cyclic GMP system. Pharmacol Toxicol72: 56–60, 1993.
43.
BeitnerR, HabermanS, CycowitzT.The effect of cyclic GMP on phosphofructokinase from rat tissues. Biochim Biophys Acta482: 330–340, 1977.
44.
BingRJ, GowanC, BoucherD, CorsiniG, DanielsCG. A new method of measuring coronary blood flow in man. JAMA205: 277–280, 1968.
45.
CowanC, DuranPVM, CorsiniG, GoldschlagerN, BingRJ. The effects of nitroglycerin on myocardial blood flow in man: Measured by coincidence counting and bolus injections of “Rubidium. Am J Cardiol24: 154–160, 1969.
46.
ArkonacBM, KerstenJR, WynsenJC, NijhawanN, WarltierDC. Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside, and nitroglycerin. Pharmacology52: 92–100, 1996.
47.
KowalukEA, FungH-L.Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. J Pharmacol Exp Ther255: 1256–1264, 1990.
MaragosCM, WangJM, HrabieJH, OppenheimJJ, KeeferLK. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res53: 564–568, 1993.
50.
MooradianDL, HutsellTC, KeeferLK. Nitric oxide (NO) donor molecules: Effect of NO release rate on vascular smooth muscle cell proliferation in vitro.J Cardiovasc Pharmacol25: 674–678, 1995.
51.
YamamotoT, CohenAM, KakarNR, YamamotoM, JohnsonPE, ChoYK, BingRJ. Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin. Biochem Biophys Res Commun257: 488–493, 1999.
52.
DudckRR, WildhirtS, ConfortA, PintoV, SuzukiH, WinderS, BingRJ. Inducible nitric oxide synthase activity in myocardium after myocardial infarction in rabbit. Biochem Biophys Res Commun205: 1671–1680, 1994.
HibbsJB, TaintorRR, VavrinZ.Macrophage cytotoxicity: Role for 1-arginine dciminase and imino nitrogen oxidation to nitrite. Science235: 473–476, 1987.
55.
KimuraA, RosetoJ, SuhK-Y, BingRJ. Dexamethasone on inducible nitric oxide synthase and nitrite/nitrate production in myocardial infarction. Proc Soc Exp Biol Med219: 138–143, 1998.
56.
SuzukiH, WolfPW, AkiyamaK, HorstmanD, GrantP, CannavinoC, BingRJ. Effect of inhibitors of inducible form of nitric oxide synthase in infarcted heart muscle. Proc Assoc Am Physicians108: 173–178, 1996.
57.
NeedlemanP, JohnsonEM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther184: 709–715, 1973.
58.
SchrörK, FörsterS, WoditschI.Online measurement of nitric oxide release from organic nitrates in the intact coronary circulation. Naunyn-Schmiedeberg's Arch Pharmacol344: 240–246, 1991.
59.
GruetterCA, LemkeSM. Dissociation of cysteine and glutathione levels from nitroglycerin-induced relaxation. Eur J Pharmacol111: 85–95, 1985.
60.
SakanashiM, MatsuzakiT, AniyaY.Nitroglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathiones-transferase activity. Br J Pharmacol103: 1905–1908, 1991.
61.
WaldmanS, RapoportR, GinsburgR, MuradF.Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol35: 3525–3531, 1986.
62.
SchroderH, LeitmanD, BennettB, WaldmanS, MuradF.Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther245: 413–418, 1988.
MünzelT, SayeghH, FreemanBA, TarpeyMM, HarrisonDG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest95: 187–194, 1995.
65.
RajagopalanS, KurzS, MünzelT, TarpeyM, FreemanBA. Griendhng KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest97: 1916–1923, 1996.
66.
MünzelT, KurzS, RajagopalanS, ThoencsM, BerringtonWR, ThompsonJA, FreemanBA, HarrisonDG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: A new action for an old drug. J Clin Invest98: 1465–14701996.
67.
MünzelT, HoltzJ, MülschA, StewartDJ, BassengeE.Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation79: 188–197, 1989.
68.
FinkB, BassengeE.Exogenous NO in contrast to endogenous NO is subject to tolerance due to enhanced O2-radical formation resulting from impaired NO-scavenging. Pfuegers Arch429: R108, 1995.
69.
BassengeE, FinkB.Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn-Schmiedeberg's Arch Pharmacol353: 363–367, 1996.
70.
BassengeE, FinkB.Suppression of nitrate-induced tolerance by vitamin C and other antioxidants. In: MoncadaJ, StamlerS, GrossS, HiggsEA Eds. The Biology of Nitric Oxide. Part 5. London: Portland Press Ltd., p 198, 1996.
71.
WatanabeH, KakihanaM, OhtsukaS, SugishitaY.Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation97: 886–891, 1998.
72.
BassengeE, FinkN, SkatchkovM, FinkB.Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest102: 67–71, 1998.
73.
WatanabeH, KakihanaM, OhtsukaS, SugishitaY.Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation96: 2545–2550, 1997.
74.
BerkenboomG, FontaineD, UngerP, BaldassarreS, PreumontN, FontaineJ.Absence of nitrate tolerance after long-term treatment with ramipril: An endothelium-dependent mechanism. J Cardiovasc Pharmacol34: 547–553, 1999.
75.
KurzS, HinkU, NickenigG, BorthayreAB, HarrisonDG, MunzelT.Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation99: 3181–3187, 1999.
76.
LamarqueD, WhittleBJR. Role of oxygen-derived metabolites in the rat gastric mucosal injury induced by nitric oxide donors. Eur J Pharmacol277: 187–194, 1995.
77.
EiserichJP, HristovaM, CrossCE, JonesAD, FreemanBA, HalliwellB, van der VlietA.Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature391: 393–397, 1998.
78.
EstévezAG, RadjR, BarbeitoI, ShinJT, ThompsonJ, BeckmanJS. Peroxynitrite induces apoptosis in PC12 cells and alters responses to neurotrophic factors. J Neurochem65: 1543–1550, 1995.
79.
VillaLM, SalasE, Darley-UsmarVM, RadomskiMV, MoncadaS.Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci U S A91: 12383–12387, 1994.
80.
WeverRM, LuscherTF, CosentinoF, RabelinkTJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation97: 108–112, 1998.
81.
HayashiT, YamadaK, EsakiT, KanoH, AsaiY, Kumar ThakurN, JayachandranM, SumiD.Iguchi A. Endothelium-dependent relaxation of rabbit atherosclerotic aorta was hot restored by control of hyperlipidemia: The possible role of peroxynitrite (ONOOO(-)). Atherosclerosis147: 349–363, 1999.
82.
CathcartMK, MorelDW, ChisolmGMIII. Monocytes and neutrophils oxidize low-density lipoprotein making it cytotoxic. J Leukocyte Biol38: 341–350, 1985.
83.
BeckmanJS, IschiropoulosH, van ZhuL, doer WoerdM, SmithC, ChenJ, HarrisonJ, MartinJC, TsaiM.Kinetics of superoxide dismutase and iron catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys298: 438–445, 1992.
KooyNW, LewisSJ, RoyallJA, YeYZ, KellyDR, BeckmanJS. Extensive tyrosine nitration in human myocardial inflammation: Evidence for the presence of peroxynitrite. Crit Care Med25: 812–819. 1997.
86.
CarmelietP.Mechanisms of angiogenesis and artcriogenesis. Nature Med6: 389–395, 2000.
87.
GalloO, MasiniE, MorbidelliL, FranchiA, Fini-StorchiI, VergariWA, ZieheM.Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst90: 587–596, 1998.
88.
WeidnerN, FolkmanF, PazzaF, BevilacquaP, AllredEN, MooreDH, MeliS, GaspariniG.Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst84: 1875–1887, 1992.
89.
FukumuraD, JainRK. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev17: 77–89, 1998.
90.
VamvakasS, SchmidtH.Just say NO to cancer?J Natl Cancer Inst89: 406–407, 1997.
91.
Cordon-CardoC.At the crossroads of inflammation and tumorigertesis. J Exp Med190: 1367–1370, 1999.
92.
ChinjeEC, StratfordU.Role of nitric oxide in growth of solid tumors: A balancing act. Essays Biochem32: 61–72, 1997.
93.
HajriA, MetzgerE, VallatF, CoffyS, HatterE, EvradS, MarescauxJ, AprahamianM.Role of nitric oxide in pancreatic tumour growth: In vivo and in vitro studies. Br J Cancer78: 841–849, 1998.
94.
TsujiiM, KawanoS, TsujiS, SawaokaH, HoriM, DuBoisRN. Cyclooxygenasc regulates angiogenesis induced by colon cancer cells. Cell93: 705–716, 1998.
95.
MorbidelliL, ChangC-H, DouglasJG, GrangerHJ, LcddaF, ZieheM.Nitric oxide mediates mitogenic effect of VEGF on coronary venule endothelium. Am J Physiol270: H411–H415, 1996.
96.
WuHM, YuanY, McCarthyM, GrangerHJ. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am J Physiol271: H1087–H1093, 1996.
97.
BingRJ, YamamotoT, KimH, GrubbsRH. The pharmacology of a new nitric oxide donor B-NOD. Biochem Biophys Res Commun275: 350–353, 2000.
